These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36054727)

  • 1. Risk-reducing mastectomy decisions among women with mutations in high- and moderate- penetrance breast cancer susceptibility genes.
    Comeaux JG; Culver JO; Lee JE; Dondanville D; McArthur HL; Quinn E; Gorman N; Ricker C; Li M; Lerman C
    Mol Genet Genomic Med; 2022 Oct; 10(10):e2031. PubMed ID: 36054727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demographics and Clinical Decision Making in Patients with Germline Moderate Penetrance Non-BRCA Mutations in Breast Cancer Related Genes.
    Ntowe KW; Thomas SM; Dalton JC; Olunuga E; Wang T; Chiba A; Plichta JK
    Ann Surg Oncol; 2024 Oct; 31(11):7290-7300. PubMed ID: 38976158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast reconstruction after risk-reducing mastectomy in BRCA mutation carriers.
    Nagura N; Hayashi N; Takei J; Yoshida A; Ochi T; Iwahira Y; Yamauchi H
    Breast Cancer; 2020 Jan; 27(1):70-76. PubMed ID: 31292927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk-reducing mastectomy in BRCA1/2 mutation carriers: factors influencing uptake and timing.
    van Driel CM; Eltahir Y; de Vries J; Jaspers JP; Oosterwijk JC; Mourits MJ; de Bock GH
    Maturitas; 2014 Feb; 77(2):180-4. PubMed ID: 24268650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia.
    Ložar T; Žgajnar J; Perhavec A; Blatnik A; Novaković S; Krajc M
    Eur J Surg Oncol; 2021 Aug; 47(8):1900-1906. PubMed ID: 33812767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1/2 mutation carriers & risk reducing mastectomy: Who undergoes surgery and potential benefits.
    Record SM; Thomas SM; Ntowe K; Chiba A; Plichta JK
    Am J Surg; 2024 Jan; 227():146-152. PubMed ID: 37827871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences among a Portuguese cohort of BRCA pathogenic/likely pathogenic variants carriers choosing risk-reducing mastectomy or intensive breast surveillance.
    Torres S; Peleteiro B; Magalhães A; Garrido L; Costa S; Fougo JL
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7529-7538. PubMed ID: 36971799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
    Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
    Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reasons for risk-reducing mastectomy versus MRI-screening in a cohort of women at high hereditary risk of breast cancer.
    Haroun I; Graham T; Poll A; Sun P; Hill K; Weitzner E; Narod S; Warner E
    Breast; 2011 Jun; 20(3):254-8. PubMed ID: 21306899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
    Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
    Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors that impact risk management decisions among women with pathogenic variants in moderate penetrance genes associated with hereditary breast cancer.
    Napoli M; Lewis J; Hopper J; Widmeyer K
    J Genet Couns; 2020 Dec; 29(6):960-970. PubMed ID: 32012395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uptake of risk-reducing surgery in BRCA gene carriers in Wales, UK.
    Long J; Evans TG; Bailey D; Lewis MH; Gower-Thomas K; Murray A
    Breast J; 2018 Jul; 24(4):580-585. PubMed ID: 29286205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Points to Consider Regarding Risk-Reducing Mastectomy in High-, Moderate-, and Low-Penetrance Gene Carriers.
    Corso G; Robson ME; Sacchini V
    Ann Surg Oncol; 2022 Sep; 29(9):5821-5825. PubMed ID: 35604619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers.
    Beattie MS; Crawford B; Lin F; Vittinghoff E; Ziegler J
    Genet Test Mol Biomarkers; 2009 Feb; 13(1):51-6. PubMed ID: 19309274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
    Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.
    Hartmann LC; Sellers TA; Schaid DJ; Frank TS; Soderberg CL; Sitta DL; Frost MH; Grant CS; Donohue JH; Woods JE; McDonnell SK; Vockley CW; Deffenbaugh A; Couch FJ; Jenkins RB
    J Natl Cancer Inst; 2001 Nov; 93(21):1633-7. PubMed ID: 11698567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk management decisions in women with BRCA1 and BRCA2 mutations.
    Morgan R; Brown A; Hamman KJ; Sampson J; Naik A; Massimino K
    Am J Surg; 2018 May; 215(5):899-903. PubMed ID: 29499861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations.
    Julian-Reynier C; Mancini J; Mouret-Fourme E; Gauthier-Villars M; Bonadona V; Berthet P; Fricker JP; Caron O; Luporsi E; Noguès C
    Eur J Hum Genet; 2011 May; 19(5):500-6. PubMed ID: 21267012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.